Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IACH MATH 2020 | CAR T-cell therapy for AML

Arnon Nagler • 7 Jun 2020
IACH MATH 2020
Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Leukemia Axicabtagene ciloleucel CAR-T Tisagenlecleucel

Arnon Nagler, MD, Sheba Medical Center, Tel-Aviv, Israel, discusses the exciting field of CAR T-cell therapy in acute myeloid leukemia (AML). Although the success of CAR T-cell therapy in other fields has not been translated into treatment for AML, Prof. Nagler reveals that research is progressing and in the future CAR T-cells for AML might be a possible treatment. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Arnon Nagler

1:21
Trends in alloSCT for good-risk AML: a longitudinal study
Arnon Nagler • 9 Dec 2023
2:15
GvHD prophylaxis post-alloSCT: PTCy versus ATG
Arnon Nagler • 9 Dec 2023
2:13
Haploidentical SCT for the treatment of secondary AML
Arnon Nagler • 9 Dec 2023
2:52
GvHD prophylaxis in AML: PTCy versus CNI
Arnon Nagler • 9 Dec 2023

Related Videos

2:24
Manipulating the gut microbiome to improve outcomes of alloSCT for hematological malignancies
Florent Malard • 11 Apr 2024
2:05
Investigating mutation order in AML using single-cell sequencing
Ravindra Majeti • 8 Apr 2024
3:12
An epitope editing approach to enable the use of targeted immunotherapy in AML
Gabriele Casirati • 9 Apr 2024
0:59
Developing LSC-targeting agents in AML: progress and current therapeutic capacity
Ravindra Majeti • 8 Apr 2024
The content of VJHemOnc is intended for healthcare professionals